COMPOUND RECORD / IPH-AGAA

IPH-AGAAПептид IPH-AGAA

PerformanceStressRecovery

Source linked

01 / OVERVIEW

About IPH-AGAA

Names in this research collection

IHP-AGAA

A research peptide evaluated in human-derived and rat muscle cultures. Marker expression is the endpoint.

Research background

A research peptide evaluated in human-derived and rat muscle cultures. Marker expression is the endpoint.

What the studies found

Lab research · 2017

Who or what was studiedHuman embryonic muscle-derived mesenchymal cells and rat primary muscle cultures.

Reported finding

Myogenic differentiation marker expression increased 2.9- and 2.8-fold at 20 and 200 ng/mL in human-derived cells.

Myf5 marker: 2.9- and 2.8-fold versus control20 and 200 ng/mL, respectively. The rat culture did not show the same differentiation response.
p53 expression: 1.6- and 1.5-fold lower20 and 200 ng/mL in human-derived cultures.
Pax7 and Ki67: About 1.2-fold changes at selected concentrationsMarker assays do not measure whole-muscle regeneration.

All reported results & study design →

Methods, dose & source notes

Study of this preparation · International Journal of Applied and Fundamental Research, original report

Cell-culture results cannot establish a clinical dose or athletic benefit. Report alternates IPH and IHP spelling.

IPH-AGAA in cultured muscle cells ↗

These highlights cover selected studies. Open a source for its methods, reported doses and full context.

Compound class: Experimental cell-culture peptide
Research collection: Actoprotection & occupational pharmacology · editorial grouping
Research institutions: No institutional affiliation recorded
Source review: Review dates and the material assessed are listed with each publication below.

02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research No human dosing study in the indexed source.
Study methods Concentration-response cell marker experiments.
Independent replication Independent replication is not established in the linked sources.
Source access Original sources and the exact review scope are linked below.
Safety evidence The linked experiments do not establish a safe human performance regimen.

Open a topic for the evidence assessment.

More findings, background and history

EVIDENCE REVIEW / 6 OCTOBER 2026

Outstanding review questions

Appraise original methods and replication; keep animal and cell findings separate from unestablished human benefit and safety.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.

Browse original study records ↗

03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2017 · IPH-AGAA in cultured muscle cellsMyf5 marker: 2.9- and 2.8-fold versus control

2017In vitroFull text available

IPH-AGAA in cultured muscle cells

· International Journal of Applied and Fundamental Research, original report

Format: International Journal of Applied and Fundamental Research, original report · Reviewed: Reported methods, results and evidence limitations

R. Roitman, J. Lerner, E. Korshun, A. Ilnitskii, N. Pozdnjakova, S. Gorelik, K. Bocharova, T. Olenskaya · International Journal of Applied and Fundamental Research, original report

Myogenic differentiation marker expression increased 2.9- and 2.8-fold at 20 and 200 ng/mL in human-derived cells.

Findings, study figures and available tables

Reported findings and study design

Myogenic differentiation marker expression increased 2.9- and 2.8-fold at 20 and 200 ng/mL in human-derived cells.

Marker expression quantified by immunocytochemistry after exposing cells to peptide concentrations.

Dose, route and schedule

In vitro concentrations of 2, 20 and 200 ng/mL. Selected responses at 20 and 200 ng/mL.

Protocol source ↗ · International Journal of Applied and Fundamental Research, original report

Reported findings and study figures · International Journal of Applied and Fundamental Research, original report
Measure	Result	Comparison, timing and statistics
Myf5 marker	2.9- and 2.8-fold versus control	20 and 200 ng/mL, respectively. The rat culture did not show the same differentiation response.
p53 expression	1.6- and 1.5-fold lower	20 and 200 ng/mL in human-derived cultures.
Pax7 and Ki67	About 1.2-fold changes at selected concentrations	Marker assays do not measure whole-muscle regeneration.

Cell-culture results cannot establish a clinical dose or athletic benefit. Report alternates IPH and IHP spelling.

Source for the extracted data ↗ · Checked 2026-11-09

Population / setting: Human embryonic muscle-derived mesenchymal cells and rat primary muscle cultures.
What was checked: International Journal of Applied and Fundamental Research, original report

Limitations & review scope

Cell-culture results cannot establish a clinical dose or athletic benefit. Report alternates IPH and IHP spelling.

Source checked 2026-11-09. See the review scope above for the material assessed.

Read the source ↗

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗